| INTRODUCTION
Tuberculosis (TB) remains high morbidity in China, especially in the northwestern areas, such as Xinjiang Uyghur Autonomous Region.
To control the prevalence of TB, early diagnosis of TB and detection of latent tuberculosis infection (LTBI) should be of great significance. 1, 2 Recently, interferon gamma release assays (IGRAs) have been introduced for the rapid diagnosis of TB and screening for LTBI, and widely used in this high TB endemic country. used IGRA in China for its high specificity and sensitivity. [3] [4] [5] This assay allows enumeration of the number of responsive effector T-cells stimulated by Mycobacterium tuberculosis (MTB)-specific antigens early secreted antigen target-6 (ESAT-6) and culture filtrate protein 10
T-SPOT.TB (Oxford Immunotec
(CFP-10), encoded in the genomic region of difference (RD) of MTB.
These two antigens are absent in most non-tuberculosis mycobacterium, including the widely used TB vaccine bacillus Calmette-Guerin (BCG) in China. 6, 7 In T-SPOT.TB test processing, peripheral blood mononulear cells (PBMCs) need to be isolated from blood samples, and then be stimulated by MTB specific antigens. So, in order to prevent the deterioration of cell functionality, the testing procedure has to be conducted within 8 hours after the blood was collected according to manufacturer's instructions.
In China, especially in the northwest provinces such as Xinjiang
Uyghur Autonomous Region, TB is highly prevalent. The prevalence of TB and incidence of new TB patients in Xinjiang region was reported as 1526/100 000 and 197/100 000-204/100 000, respectively.
8,9
However, T-SPOT.TB test is still unavailable in many remote countylevel hospitals in this region. Therefore, samples collected from these hospitals have to be sent to laboratories in Urumqi for T-SPOT.TB
testing. The shipping of samples from county hospitals to Urumqi city usually goes far beyond 8 hours, the maximum sample storage time according to the manufacturer's instructions. This may subsequently lead to inaccurate T-SPOT.TB result due to the decrease in cell counts and functionality. 10, 11 In order to prevent decreased response of PBMCs to TB-specific antigenic stimulation in T-SPOT.TB testing caused by long storage time, T-Cell Xtend kit (Oxford Immunotec Ltd., Abingdon UK) was introduced to this test.
T-Cell Xtend reagent is designed for the isolation of lymphocytes from peripheral whole blood samples. Previous study showed that cell counts and functionality of T-cells prepared with T-Cell Xtend from overnight samples remain similar to those obtained from fresh blood. 12, 13 This may make T-SPOT.TB available to patients in hospitals with some distance by treating delayed blood samples with T-Cell Xtend.
In this study, we investigated the performance of T-Cell Xtend reagent in T-SPOT.TB test for samples stored up to 36 hours (maximum time needed for the delivery of samples from hospitals in remote areas to laboratories in Urumqi). As this is the first systematical study on the performance of T-Cell Xtend in a novel population (Uyghur) and Asian region, the results of this study may provide additional data for facilitating rational use of this reagent in more extensive regions and in different ethnic groups. Furthermore, for the first time, we describe the performance of T-Cell Xtend in patients above the age of 70 yrs in the present study.
| MATERIALS AND METHODS

| Subjects and study design
The study protocol was in compliance with the Declaration of Helsinki, Table 1 . The patients with insufficient WBCs counts were finally excluded from T-SPOT.TB testing, all the subjects here were BCG vaccinated. Four mL and 9 mL blood was collected in lithium heparin tubes (Becoton, Dickinson), respectively. The 4 mL lithium heparin blood was used for T-SPOT.TB testing within 8 hours after being collected. The 9 mL lithium heparin blood was left to stand at room temperature for 36 hours. After 36 hours of storage, the 9 mL blood was divided into two 15 mL centrifuge tubes, 4 mL blood in each tube. Then one tube was treated with T-Cell Xtend reagent, the other tube was untreated with TCX and served as an untreated control.
| T-Cell Xtend procedure
To test the performance of T-Cell Xtend (TCX, TTK.610 Oxford Immunotec Ltd., Abingdon, UK), 4 mL lithium heparin (LH) blood was treated with TCX. Twenty-five μL TCX was added to each mL LH blood, namely, 100 μL for 4 mL LH blood according to the standard protocol. After addition of TCX, tubes were inverted five times and left to stand at room temperature for 20 minutes before starting the isolation of PBMCs.
| Isolation of PBMCs
Peripheral blood mononuclear cells were isolated by Ficoll-Hypaque gradient centrifugation. Briefly, blood sample were mixed with 4 mL RPMI-1640 (Gibco #21875, Invitrogen, Breda, The Netherlands) and then transferred into a 15 mL Leucosep tube prefilled with 3 mL Fillco and containing a high grade polyethylene barrier (Haoyang Biotect Ltd., Tianjin, China). Tubes were centrifuged at room temperature at 1000 g without brake for 22 minutes. The PBMCs layer was aspirated and transferred to another 15 mL tube, RPMI-1640 was subsequently added to final total volume of 10 mL. After centrifuging at 600 g for 7 minutes, the supernatant was discarded and the pellet was 
| Cell counts and lymphocytes proportion analysis
Cell 
| Tuberculosis diagnosis and exclusion
The inclusion criterion for definitive/confirmed active tuberculosis was based on clinical manifestations, microbiological/histopathological examinations, bronchoscopic/laparoscopic findings, radiological findings, and clinical response to anti-TB therapy after a follow-up of at least 3 months. Briefly, patients with specimens yielded positive T A B L E 1 Characterization of patients enrolled in the study (n=99) MTB culture, caseating granulomas presented in bronchoscopic/ laparoscopic imaging, biopsy or surgical specimens, or manifestations and X-ray graphics successfully response to anti-TB therapy for at least 3 months were finally diagnosed as confirmed active TB.
Patients were excluded from active TB if other diagnoses were made or if clinical improvement occurred without anti-TB therapy.
| Statistics analysis
Data analysis was performed with IBM SPSS Statistics 22 (IBM, Armonk,
NY, USA). WBCs counts and lymphocytes proportion in PBMCs and
SFCs in (positive control well) PCW in each sample group were compared with independent t tests. Cohen's kappa coefficient was calculated to establish the agreement of T-SPOT.TB results between paired sample groups. Positive rate of T-SPOT results was analyzed with
Person chi-square tests.
| RESULTS
| WBC counts in PBMCs
We enumerated white blood cells (WBCs, including lymphocytes, monocytes and granulocytes) in peripheral blood mononuclear cells 
| Lymphocytes proportion in PBMCs
Lymphocytes proportions in the PBMCs were investigated with all the 99 paired specimens. After 36 hours of storage, the proportion of lymphocytes in PBMCs collected from TCX-treated blood samples was 86.5±4.8%, significantly higher when compared with the proportion of lymphocytes obtained from control samples (82.7±5.8%, P<.001).
Still, the percentage of lymphocytes in PBMCs from untreated specimens (59.7±9.0%) was significantly lower than the lymphocytes percentage in PBMCs from freshly isolated controls (P<.001; Figure 3 ). To sum up, these results indicated that delayed PBMCs isolation would cause rapid decrease in proportion of lymphocytes in PBMCs, and this effect could be neutralized by T-Cell Xtend treatment even the blood samples were left to stand for 36 hours. However, the agreement between T-SPOT.TB results from controls F I G U R E 2 Mean white blood cell counts in peripheral blood mononuclear cells prepared from freshly isolated controls (LH) and blood samples-treated (TCX) and untreated (UTCX) with T-cell Xtend after being delayed for 36 hours 
| T-SPOT.TB results
| Effect of TCX on SFCs in positive control well
We evaluated the SFCs in the positive control well (PCW) in the 58 paired results. SFCs of TCX samples were significantly higher than that of control samples (299±101 vs 266±94, P<.05). As we postulated, SFCs formed in the PCW of UTCX samples (204±67) was significantly lower than that of both TCX samples and control samples (both P<.001; Figure 5 ).
We also compared SFCs of PCW between TCX samples and controls in both T-SPOT.TB positive and negative samples. However, no significant difference in SFCs was observed. Moreover, SFCs in PCW of TCX samples were significantly higher than that of UTCX samples and the control samples (P<.05, data not shown), no matter whether the T-SPOT.TB results were positive or not.
| T-Cell Xtend improved the performance of T-SPOT.TB in elderly population
As TCX-treated samples showed higher WBC counts and lympho- Positive rates of T-SPOT.TB results from freshly isolated controls (LH), T-cell-treated (TCX) and untreated (UTCX) samples 36 h after blood collection. P values were obtained from Person chi-square analysis.
T A B L E 2 Positive rate (PR) analysis of T-SPOT.TB results
Group
F I G U R E 4 Cross tabs of T-SPOT.TB results. Results obtained from T-cell Xtendtreated (TCX, A) and untreated (UTCX, B)
samples after being stored for 36 hours were both presented with T-SPOT.TB results from freshly isolated controls (LH). "−": Negative; "+": Positive 
| DISCUSSION
T-SPOT.TB is an in vitro test that relies on T-cell mediated immune response, so cell counts and functionality of lymphocytes in the PBMCs are of paramount importance to this test. 15, 16 In the present study, we evaluated the performance of T-Cell
Xtend on blood specimens delayed up to 36 hours. The WBC counts in the PBMCs from samples treated with TCX 36 hours after the phlebotomy were significantly higher than in the PBMCs from corresponding untreated samples and freshly isolated controls. Bouwman et al. 12 showed that proportion of lymphocytes in the PBMCs did not differ among the three groups of samples (TCX, UTCX and controls).
However, this does not apply for the results we obtained here, we observed significant higher lymphocytes percentage in TCX group than in the controls. Both WBC counts and lymphocytes proportion were the lowest in the PBMCs from samples untreated with TCX after 36 hours of storage among these three groups. In summary, these results indicate that extended sample storage times (up to 36 hours) may lead to rapid decrease in WBCs and lymphocytes percentage in the PBMCs, and this decrease can be neutralized by treating samples with TCX before the initiation of isolation procedure. However, whether TCX treatment is able to restore cell functionality need further investigation.
These results also confirmed that long storage times would lead to the deterioration of the blood samples, which may subsequently result in false negative T-SPOT.TB results. 10 We also analyzed spots-forming ability of the PBMCs in the positive control well, which directly reflected the qualities of samples, and untreated (UTCXelder, B) samples after being stored for 36 hours were both presented with T-SPOT.TB results from freshly isolated controls (LHelder). "−": Negative; "+": Positive the observations of previous studies, and also provide data for the extensive utility of T-SPOT.TB in Asian counties.
We also noticed that, in the 23 elderly patients (above the age of [21] [22] [23] [24] In conclusion, we confirmed the performance of TCX in T-SPOT.
TB testing in a novel population, and provided data for its using in
Asian countries in this study. By treating with TCX, blood samples can be stored for up to 36 hours without any impacts on the T-SPOT.
TB results. Utilizing of TCX offers greater flexibilities for sample receiving and experiment processing to routine laboratories, which would subsequently facilitate the availabilities of T-SPOT.TB to some remote areas. This is of great significance for TB diagnosis in high prevalence and low-income Asian countries. Meanwhile, we found that treating blood samples with TCX can improve the positive rate of T-SPOT.TB results in elderly patients, which may help improve the performance of T-SPOT.TB in immunosufficient or immunosuppressed patients.
